Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009)
Clinical trial NCT04191135 · COMPLETED
Trial details
- NCT number
- NCT04191135
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-12-19
- Primary completion
- 2022-12-15
- Enrollment
- 462
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.